IFNL4 ss469415590 variant is a better predictor than rs12979860 of pegylated interferon-alpha/ribavirin therapy failure in hepatitis C virus/HIV-1 coinfected patients

AIDS. 2014 Jan 2;28(1):133-6. doi: 10.1097/QAD.0000000000000052.

Abstract

A new transiently induced region (interferon-λ 4 protein; IFNL4) harbouring a dinucleotide variant ss469415590 (TT or ΔG), upstream of IFNL3 (IL28B), was recently found to be associated with hepatitis C virus (HCV) clearance. To determine the effect of IFLN4 ss469415590 variation on the HCV response to IFN-based therapy in HCV/HIV-1 coinfected patients, ss469415590 was genotyped in a cohort of 207 patients from our clinic. Treatment failure occurred in 77% of minor ΔG-allele carriers versus 48% of noncarriers, indicating that the ΔG allele was strongly associated with treatment failure. Importantly, multivariate logistic analysis revealed that ss469415590 genotype was a better predictor of treatment failure than rs12979860.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antiviral Agents / therapeutic use*
  • Cohort Studies
  • Coinfection / drug therapy
  • Female
  • Genetic Predisposition to Disease
  • Genotype
  • HIV Infections / complications*
  • Hepatitis C, Chronic / complications*
  • Hepatitis C, Chronic / drug therapy*
  • Humans
  • Interferon-alpha / therapeutic use*
  • Interleukins / genetics*
  • Male
  • Polymorphism, Genetic
  • Ribavirin / therapeutic use*
  • Treatment Failure

Substances

  • Antiviral Agents
  • IFNL4 protein, human
  • Interferon-alpha
  • Interleukins
  • Ribavirin